series-a
Stage
1
Investors
About
Biograph 55 develops a bispecific antibody immunotherapy (B%%-001) that targets a unique regulatory B-cell population in solid tumors to potentially treat cancer patients unresponsive to checkpoint inhibitors, and is also developing therapies to eliminate plasma cells involved in autoimmune diseases.
Explore Biograph 55's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.